Premium
Recombinant human interferon beta in relapsing–remitting multiple sclerosis: a review of the major clinical trials
Author(s) -
Chofflon M.
Publication year - 2000
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1046/j.1468-1331.2000.t01-1-00001.x
Subject(s) - medicine , multiple sclerosis , interferon beta 1a , placebo , relapsing remitting , clinical trial , table (database) , recombinant dna , interferon beta , immunology , pathology , alternative medicine , data mining , biochemistry , chemistry , computer science , gene
In this article the percentage increase in relapse‐free patients at 1 year as shown in Table 3 was presented incorrectly. The correct information is that the results reported for IFN‐β‐1a 66 mcg (59%) and 132 mcg (87%) are both statistically significant ( P < 0.05) versus placebo, and should therefore have been marked with an asterisk (*), as this is the case for all other statistically significant results displayed in the table. The author apologizes for this error. The corrected version of the table appears below.